NasdaqGS:HOLX - アナリストの将来予測と過去の財務データ ( )USD Millions
日付	収益	収益	フリー・キャッシュフロー	営業活動によるキャッシュ	平均アナリスト数
9/30/2026	4,500	947	1,128	1,206	13
9/30/2025	4,253	858	1,048	1,171	16
9/30/2024	4,023	776	846	1,048	15
6/29/2024	3,988	702	1,015	1,177	N/A
3/30/2024	3,961	467	949	1,104	N/A
12/30/2023	3,969	515	859	1,018	N/A
9/30/2023	4,030	456	901	1,051	N/A
7/1/2023	4,038	484	832	961	N/A
4/1/2023	4,057	753	841	959	N/A
12/31/2022	4,466	990	1,696	1,815	N/A
9/24/2022	4,863	1,302	1,999	2,126	N/A
6/25/2022	5,226	1,512	2,283	2,423	N/A
3/26/2022	5,392	1,552	2,598	2,755	N/A
12/25/2021	5,494	1,716	2,068	2,245	N/A
9/25/2021	5,632	1,872	2,146	2,330	N/A
6/26/2021	5,663	2,038	2,108	2,307	N/A
3/27/2021	5,317	1,907	1,677	1,867	N/A
12/26/2020	4,536	1,384	1,263	1,433	N/A
9/26/2020	3,776	1,115	740	897	N/A
6/27/2020	3,295	497	573	702	N/A
3/28/2020	3,325	453	518	643	N/A
12/28/2019	3,387	84	536	659	N/A
9/28/2019	3,367	-204	536	650	N/A
6/29/2019	3,315	-30	520	634	N/A
3/30/2019	3,287	-11	596	705	N/A
12/29/2018	3,258	-419	562	668	N/A
9/29/2018	3,218	-111	627	733	N/A
6/30/2018	3,207	-79	560	667	N/A
3/31/2018	3,189	-132	N/A	21	N/A
12/30/2017	3,116	1,076	N/A	8	N/A
9/30/2017	3,059	756	N/A	8	N/A
7/1/2017	2,983	765	N/A	70	N/A
4/1/2017	2,894	790	N/A	729	N/A
12/31/2016	2,872	332	N/A	796	N/A
9/24/2016	2,833	331	N/A	798	N/A
6/25/2016	2,809	264	N/A	802	N/A
3/26/2016	2,785	208	N/A	797	N/A
12/26/2015	2,747	187	N/A	804	N/A
9/26/2015	2,705	132	N/A	797	N/A
6/27/2015	2,641	135	N/A	685	N/A
3/28/2015	2,580	116	N/A	601	N/A
12/27/2014	2,549	52	N/A	513	N/A
9/27/2014	2,531	17	N/A	508	N/A
6/28/2014	2,477	-1,125	N/A	455	N/A
3/29/2014	2,470	-1,147	N/A	543	N/A
12/28/2013	2,458	-1,181	N/A	488	N/A
9/28/2013	2,492	-1,173	N/A	494	N/A

アナリストによる今後の成長予測

収入対貯蓄率: HOLXの予測収益成長率 (年間14.6% ) は貯蓄率 ( 2.4% ) を上回っています。

収益対市場: HOLXの収益 ( 9.8% ) US市場 ( 14.9% ) よりも低い成長が予測されています。

高成長収益: HOLXの収益は増加すると予測されていますが、大幅には増加しません。

収益対市場: HOLXの収益 ( 5.3% ) US市場 ( 8.7% ) よりも低い成長が予測されています。

高い収益成長: HOLXの収益 ( 5.3% ) 20%よりも低い成長が予測されています。

一株当たり利益成長率予想

将来の株主資本利益率

将来のROE: HOLXの自己資本利益率は、3年後には低くなると予測されています ( 18.1 %)。

Hologic 将来の成長

Future 基準チェック /16

主要情報

今後の成長に関する最新情報

Hologic, Inc. Provides Earnings Guidance for the Fourth Quarter of 2024

Hologic, Inc. Just Beat EPS By 32%: Here's What Analysts Think Will Happen Next

Hologic, Inc. Revises Earnings Guidance for the Fiscal Year 2024

Hologic, Inc. Provides Revenue Guidance for the First Quarter of 2024

Hologic, Inc. Provides Earnings Guidance for the First Quarter and Full-Year Fiscal 2024

Consensus EPS estimates fall by 22%

Recent updates

Hologic, Inc. Provides Earnings Guidance for the Fourth Quarter of 2024

Third quarter 2024 earnings: Revenues exceed analysts expectations while EPS lags behind

Hologic, Inc. (NasdaqGS:HOLX) completed the acquisition of Endomagnetics Ltd. for approximately $310 million.

Is There Now An Opportunity In Hologic, Inc. (NASDAQ:HOLX)?

Hologic, Inc. to Report Q3, 2024 Results on Jul 29, 2024

Now 19% undervalued after recent price drop

Now 20% undervalued after recent price drop

These 4 Measures Indicate That Hologic (NASDAQ:HOLX) Is Using Debt Reasonably Well

Now 20% undervalued after recent price drop

Now 20% undervalued after recent price drop

Returns At Hologic (NASDAQ:HOLX) Appear To Be Weighed Down

Hologic: Women's Health Play Looks Healthier Itself

Second quarter 2024 earnings: Revenues exceed analysts expectations while EPS lags behind

Hologic, Inc. Reports Impairment of Intangible Assets for the Second Quarter Ended March 30, 2024

Hologic, Inc. (NasdaqGS:HOLX) signed a definitive agreement to acquire Endomagnetics Ltd. for approximately $310 million.

Getting In Cheap On Hologic, Inc. (NASDAQ:HOLX) Might Be Difficult

Now 20% undervalued

Calculating The Intrinsic Value Of Hologic, Inc. (NASDAQ:HOLX)

Hologic, Inc. to Report Q2, 2024 Results on May 02, 2024

Hologic (NASDAQ:HOLX) Has A Pretty Healthy Balance Sheet

Independent Director notifies of intention to sell stock

Now 20% undervalued

Hologic, Inc. and Biotheranostics, Inc. Announces Newly Published Study Results Reveal That Use of the Breast Cancer Index®? Test

Now 20% undervalued

Why Hologic, Inc. (NASDAQ:HOLX) Could Be Worth Watching

Hologic: Prospects For Growth As Headwinds Disappear

We Think You Can Look Beyond Hologic's (NASDAQ:HOLX) Lackluster Earnings

Hologic, Inc. Just Beat EPS By 32%: Here's What Analysts Think Will Happen Next

First quarter 2024 earnings: EPS and revenues exceed analyst expectations

Hologic, Inc. Revises Earnings Guidance for the Fiscal Year 2024

We Like These Underlying Return On Capital Trends At Hologic (NASDAQ:HOLX)

Now 21% undervalued

Hologic, Inc., Annual General Meeting, Mar 07, 2024

Namal Nawana Announces Not to Stand for Re-Election to the Board of Hologic, Inc

Now 21% undervalued

Hologic, Inc. Provides Revenue Guidance for the First Quarter of 2024

Hologic, Inc. to Report Q1, 2024 Results on Feb 01, 2024

Independent Director notifies of intention to sell stock

The Price Is Right For Hologic, Inc. (NASDAQ:HOLX)

Are Investors Undervaluing Hologic, Inc. (NASDAQ:HOLX) By 25%?

Hologic, Inc. Promotes Essex D. Mitchell to Chief Operating Officer

Chairman exercised options and sold US$2.1m worth of stock

Hologic, Inc. Provides Earnings Guidance for the First Quarter and Full-Year Fiscal 2024

Full year 2023 earnings: EPS misses analyst expectations

Hologic, Inc. (NasdaqGS:HOLX) announces an Equity Buyback for $500 million worth of its shares.

We Think Hologic (NASDAQ:HOLX) Can Stay On Top Of Its Debt

Should You Think About Buying Hologic, Inc. (NASDAQ:HOLX) Now?

Hologic, Inc. to Report Q4, 2023 Results on Nov 09, 2023

Slowing Rates Of Return At Hologic (NASDAQ:HOLX) Leave Little Room For Excitement

Nanaz Mohtashami Elected to Hologic, Inc.'S Board of Directors

Hologic, Inc.'s (NASDAQ:HOLX) Intrinsic Value Is Potentially 35% Above Its Share Price

Consensus EPS estimates fall by 22%

Hologic, Inc. Reports Impairment Charges for the Third Quarter Ended July 1, 2023

New minor risk - Earnings quality

Third quarter 2023 earnings: Revenues exceed analysts expectations while EPS lags behind

Hologic, Inc. Revises Earnings Guidance for the Fiscal Year 2023

We Think Hologic (NASDAQ:HOLX) Can Stay On Top Of Its Debt

Why Hologic, Inc. (NASDAQ:HOLX) Could Be Worth Watching

Hologic, Inc. to Report Q3, 2023 Results on Jul 31, 2023

Return Trends At Hologic (NASDAQ:HOLX) Aren't Appealing

Calculating The Fair Value Of Hologic, Inc. (NASDAQ:HOLX)

Hologic, Inc. Announces FDA Clearance of Panther Fusion SARS-CoV-2/Flu A/B/RSV Assay

Insider recently sold US$200k worth of stock

Insider notifies of intention to sell stock

Second quarter 2023 earnings: EPS and revenues exceed analyst expectations

We Think Hologic (NASDAQ:HOLX) Can Stay On Top Of Its Debt

What Does Hologic, Inc.'s (NASDAQ:HOLX) Share Price Indicate?

Hologic's (NASDAQ:HOLX) Returns On Capital Are Heading Higher

Hologic, Inc. Announces Approval of NovaSure V5 Global Endometrial Ablation Device in Canada and Europe